Trichomoniasis

  • Larry E. Millikan

Abstract

A fairly frequent problem is infection by the urogenital protozoan Trichomonas vaginalis. It is perhaps the most common clinically recognized sexually transmitted disease in the United States, with about 2.5 million new cases occurring annually. Approximately 180 million new cases occur each year worldwide [1]. The infection has a continuous endemic source, for as many as half of the female carriers are totally asymptomatic. Newer treatments have greatly improved therapy for this disease, but diagnosis and the detection of carriers remain significant challenges. Symptomatic or asymptomatic urethritis or vaginitis due to T. vaginalis is the usual scenario. The spectrum of symptoms associated with this disease is wide. Ultimately, the diagnosis is established by identifying the causative organisms.

Keywords

Estrogen Assure Candida Metronidazole Schiff 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Krieger JN, Holmes KK, Spence MR, et al: Geographic variation among isolates of Trichomonas vaginalis: Demonstration of antigenic heterogenicity by using monoclonal antibodies and the indirect immunofluorescence technique. J Infect Dis 152(5):979–984, 1985.PubMedCrossRefGoogle Scholar
  2. 2.
    Wisdom R, Dunlop EMC: Trichomoniasis: Study of the disease and its treatment in women and men. Br J Vener Dis 41:90–95, 1965.PubMedGoogle Scholar
  3. 3.
    Sweet RL: Importance of differential diagnosis in acute vaginitis. Am J Obstet Gynecol 152:7:921–923; 1985.Google Scholar
  4. 4.
    Jones JG, Yamauchi T, Lambert B: Trichomonas vaginalis infestation in sexually abused girls. AJDC 139:846–847, 1985.PubMedGoogle Scholar
  5. 5.
    Fouts AC, Kraus SJ: Trichomonas vaginalis: Reevaluation of its clinical presentation and laboratory diagnosis. J Infect Dis 141:137–142, 1980.PubMedCrossRefGoogle Scholar
  6. 6.
    Alderete JF, Guillermo EG: Specific nature of Trichomonas vaginalis parasitism of host cell surfaces. Infect Immunol 50:701–703, 1985.Google Scholar
  7. 7.
    Gardner WA, Culberson DE, Bennett BD: Trichomonas vaginalis in the prostate gland. Arch Pathol Lab Med 110:430–432, 1986.PubMedGoogle Scholar
  8. 8.
    Wherton A, Honigberg BM: Structure of trichomonads as revealed by scanning electron microscopy. J Protozool 26:56–62, 1979.Google Scholar
  9. 9.
    Chang TH, Tsing SY, Tzeng S: Monoclonal antibodies against Trichomonas vaginalis. Hybridoma 5:43–51, 1986.CrossRefGoogle Scholar
  10. 10.
    Connelly RJ, Torian BE, Stibbs HH: Identification of a surface antigen of Trichomonas vaginalis. Infect Immunol 49:270–214, 1985.Google Scholar
  11. 11.
    Wright RA, Judson FN: Relative and seasonal incidences of the sexually transmitted diseases: A two year statistical review. Br J Vener Dis 54:433–439, 1978.PubMedGoogle Scholar
  12. 12.
    Krieger JN: Urologic aspects of trichomoniasis. Invest Urol 18:411–418, 1981.PubMedGoogle Scholar
  13. 13.
    Dunlop EMC, Wisdom AR: Diagnosis and management of trichomoniasis in men and women. Br J Vener Dis 41:85–90, 1965.PubMedGoogle Scholar
  14. 14.
    Lossick JG: Treatment of Trichomonas vaginalis infections. Infect Dis 4(Suppl.):801–818, 1987.Google Scholar
  15. 15.
    U.S. Department of Health and Human Services: STD Treatment Guidelines 1985. Washington, D.C.: U.S. Government Printing Office, 1985.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Larry E. Millikan

There are no affiliations available

Personalised recommendations